STOCK TITAN
  1. Home
  2. News
  3. MNK

Mallinckrodt Plc - MNK STOCK NEWS

Welcome to our dedicated news page for Mallinckrodt Plc (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mallinckrodt Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mallinckrodt Plc's position in the market.

News
Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations
Rhea-AI Summary
Mallinckrodt initiates voluntary prepackaged Chapter 11 proceedings with overwhelming support of key stakeholders, including 85%+ of debtholders. Expects to reduce total funded debt by $1.9 billion and increase free cash flow generation. Continues to operate normally, serve customers, and deliver therapies to patients. Vendors and suppliers expected to be paid in full. Court approval expected for continued operations and payment of employee wages and benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan
Rhea-AI Summary
Mallinckrodt announces Restructuring Support Agreement to reduce debt by $1.9 billion and increase free cash flow generation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.22%
Tags
none
-
News
Buxton Helmsley Issues Letter to Mallinckrodt Plc. Directors Regarding Bankruptcy Negotiations and Financial Disclosure Violations
Rhea-AI Summary
Buxton Helmsley Group accuses Mallinckrodt of accounting and securities fraud, highlights inaccurate representations of CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.69%
Tags
none
News
Mallinckrodt plc Reports Second Quarter 2023 Financial Results and Reaffirms Full Year Guidance
Rhea-AI Summary
Mallinckrodt reports Q2 net sales of $475.0M, a 1.3% YoY growth. Net loss of $747.8M, adjusted EBITDA of $144.0M, and cash on hand of $480.6M. Terlivaz launch exceeds expectations with 50% formulary access. Liquidity update: cash balance of $550M, entered forbearance agreements with lenders and noteholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.38%
Tags
earnings
-
News
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.95%
Tags
conferences
-
News
Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
clinical trial
News
Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Continued Evidentially False Statements of Financials
Rhea-AI Summary
The Buxton Helmsley Group has issued an open letter to Mallinckrodt's Board of Directors, accusing the company of violating accounting standards and securities laws. BHG demands that Mallinckrodt restate its recent filings and call an extraordinary general meeting of investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.93%
Tags
none
-
News
Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.19%
Tags
earnings
-
News
Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
clinical trial
News
Mallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact Awards
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.89%
Tags
none
Stock MNK logo
Mallinckrodt Plc

NYSE:MNK

MNK Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MNK Stock Data

4.52M
5.72M
10.09%
96.64%
13.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
College Business Technology Park Cruiserath

About MNK

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit